Saturday, April 21, 2018

Big pharmaceutical players boost credibility in the Canadian cannabis industry | Finance

Canada’s largest retail pharmacy chain, Shoppers Drug Mart continues to lend possibly the most important voice of credibility to the emerging legal cannabis market-so far, having signed supplier deals with three of Canada’s largest cannabis growers, and leaving the door open for more to come.

With over 1,250 stores across Canada, the chain owned by Loblaw Companies Limited is a national retail heavyweight. So when Shoppers Drug Mart signed its latest supply deal with cannabis giant Aurora Cannabis, it marked the fourth supplier deal the retailer has inked, and the third with a Canadian major.

Two of the other companies that have already inked agreements with the retailer were Aphria Inc., and MedReleaf Corp., late last year. The retail vote of confidence for the emerging cannabis sector started early-Parent company Loblaw Companies Ltd. applied in October 2016 for a license to dispense medical marijuana.

See also:

Other pharmacies such as Lovell Drugs and PharmaChoice have already signed deals with other cannabis suppliers; However, it’s the intensity of the spotlight that Shoppers Drug Mart casts that lends to speculation of which company will be the next to garner the retailer’s favorable access to mainstream consumers. One potential new cannabis supplier for Shoppers Drug Mart could be up-and-comer MYM Nutraceuticals, which is in line to have Canada’s largest cannabis greenhouse facility in Weedon, Quebec, and is partnered on Australia’s largest in New South Wales.

How many suppliers that Shoppers Drug Mart will carry is still yet to be determined. Should an MYM Nutraceuticals or another outfit join the ranks of Aphria Inc. and now Aurora Cannabis, it would be yet another significant stamp of approval given by a leading retailer in the leadup to legalization.

Shoppers like big growers

The addition of Aurora Cannabis to the Shoppers Drug Mart portfolio was another signal that bigger is better to the retailer. Primary to the deal is the expectation that Aurora’s products will be sold online, according to the press release. 

“The Shoppers and Aurora brands are trusted to deliver high-quality products and excellent customer service,” said Terry Booth, CEO of Aurora Cannabis. “Partnering with Shoppers Drug Mart, Canada’s largest pharmacy retailer, is yet another validation of the scale and maturity of our company, and of the demand for Aurora’s medical cannabis. With its massive facility located adjacent to the Edmonton International Airport, Aurora is one of the largest producers in the country operating today.”

Not to be outdone, fellow Shoppers Drug Mart supplier, MedReleaf recently announced the purchase of 164-acre property in Exeter, Ontario, which includes 1 million square feet of existing greenhouse. The property adds 105,000 kilograms of cannabis production capacity annually to MedReleaf’s balance sheet.

However, it’s the upcoming 1.5 million square feet of growing space planned by MYM Nutraceuticals in Weedon, Quebec that stands to be the largest project in the country once completed. Once coupled with the company’s primary facility in Laval, Quebec, and with its international ventures in Australia, and Colombia, MYM should have a line of suitors that could very well include Shoppers Drug Mart in the coming months.

MYM’s massive footprints

In the lead-up to construction on its massive 1.5 million square-foot facility at Weedon, MYM Nutraceuticals received a boost of confidence and cash from a recent $10,000,000 financing that will move the company closer to its goals in 2018.

“All of us at MYM are very excited about the future of our company,” said Rob Gietl, CEO of MYM in the accompanying press release. “This excitement extends to our family and friends who have participated in this non-brokered financing. We have many major milestones to achieve this year that will shape MYM for years to come. Continued global expansion and leveraging the relationships we have built, will ensure that MYM and its shareholders have a bright future.”

The net proceeds are intended to be used towards general working capital and corporate purposes as the company pursues development on its two Quebec production projects, and its partnered 1.2 million square foot production facility dubbed the Northern Rivers Project in New South Wales, Australia.

At the Weedon, Quebec project, MYM currently owns 75% (which goes up to 90% upon completion), and is set to help the municipality become the official cannabis capital of Canada. While there are other mega-greenhouse projects in other provinces in Canada, MYM’s decision to house their operations in Quebec was very strategic- From an economic perspective, it can’t be ignored how cheap Quebec’s costs are.

Quebec labor costs on average 34% less than in the US, and 16% less than in G7 countries. Electricity is 36% cheaper than in the US, and 49% lower, on average, than in the G7 countries. Quebec’s taxes on investment are the lowest in Canada, and more importantly lower than the average of the US, G7 countries, and the OECD countries. The province offers an investment tax credit that covers up to 24% of the cost of newly purchased manufacturing and processing equipment and reimburses sales tax on capital goods.

Once MYM’s Weedon location is opened, there’s a possibility that it can provide MYM with a quantity-, and location-based cost advantage that could benefit them to the point of making a deal with a retail giant such as Shoppers Drug Mart. With cash in hand, and a steady momentum, it could be a good year for MYM Nutraceuticals.



Source link

KL1333 receives FDA ODD for mitochondrial diseases

NeuroVive Pharmaceutical AB has been granted Orphan Drug Designation for its project KL1333 for treatment of inherited mitochondrial respiratory chain diseases…

KL1333

NeuroVive Pharmaceutical AB the mitochondrial medicine company, has announced that it has been granted Orphan Drug Designation by the United States FDA Office of Orphan Products Development for its project KL1333 for treatment of inherited mitochondrial respiratory chain diseases (MRCD).

Orphan drug designation (ODD) will give the KL1333 program extra access to regulatory and scientific advice and interactions at the FDA and may enable a focused development program and speedy approval process. ODD opens up for market exclusivity for seven years within US for NeuroVive´s KL1333, when authorised for marketing.

“The ODD approval by the US FDA is a validation of the quality of the KL1333 documentation to date and yet an important milestone for NeuroVive and the KL1333 project. The ODD will be beneficial to us in our efforts to rapidly document the effects and safety of KL1333 in genetic mitochondrial diseases and bring this novel treatment opportunity to the market and patients who are in great need of it,” said Erik Kinnman, CEO, NeuroVive.

KL1333 has been developed by the South Korean pharmaceutical company Yungjin Pharm and has in pre-clinical models been shown to increase mitochondrial aerobic energy production, while limiting the accumulation of lactate, counteracting the formation of free radicals and lead to other long-term positive effects on energy metabolism such as the formation of new mitochondria.

NeuroVive was 2017 granted exclusive rights from Yungjin Pharm to develop and commercialise KL1333 globally, except in Korea and Japan where Yungjin Pharm retains its exclusive rights. The companies will develop KL1333 within their respective territories collaborating closely on an international level to utilise possibilities for synergies. The first clinical phase I study has recently recruited its last healthy volunteer and results are expected by June. NeuroVive plans to start the next clinical phase I multiple ascending dose study in the second half of 2018.          

In the EU, Orphan Drug Designation has been obtained for the treatment of the genetic mitochondrial disease: Mitochondrial Myopathy, Encephalopathy, Lactic acidosis and Stroke-like episodes (MELAS).

Source link